A double chin is the dreaded sight faced by many people looking into a mirror。
許多人照鏡子時看到自己的雙下巴都會嚇一跳。
Now, a U.S. company claims to have invented an injection which can banish that chin bulge。
現(xiàn)在，一家美國公司宣稱已經(jīng)研發(fā)出一種可以消除下巴贅肉的注射藥物。
ATX-101, an experimental drug made by California-based Kythera Biopharmaceuticals, is injected into the skin over a series of treatments spaced no less than one month apart。
該公司名為基西拉生物制藥(Kythera Biopharmaceuticals)，總部位于加利福尼亞。其研發(fā)出的試驗藥物ATX-101在一系列的治療之后不到一個月就可以注射到皮膚中。
The drug is a type of deoxycholic acid - a naturally-occurring molecule that helps the body break down fat, according to Kythera's website。
基西拉公司網(wǎng)站上稱該藥物屬于脫氧膽酸——是一種自然形成的分子，能幫助身體分解脂肪。
It acts 'immediately on targeted fat cells' but is 'rapidly cleared' from the chin, leaving surrounded tissue largely unaffected, Kythera claims。
基西拉表示它能對“目標(biāo)脂肪細(xì)胞”迅速發(fā)揮效用，完成使命后會從下巴中“立馬消失”，不會對周圍組織造成什么影響。
It says fat under the chin is influenced by ageing and genetics, and can often not be changed by diet and exercise alone。
該公司還稱下巴中的脂肪會受到衰老和基因的影響，并且不會僅僅因為節(jié)食和鍛煉就能夠有所改變。
While this area of the face is important to patients, it is undertreated, according to Kythera。
基西拉說盡管臉部的下巴部位對于患者來說非常重要，但現(xiàn)在缺少相關(guān)的治療措施。
ATX-101 not yet been approved by the Food and Drug Administration (FDA)， the body that regulates medicines and cosmetics in the U.S。
美國食品和藥物管理局尚未批準(zhǔn)ATX-101面世。
But in clinical trials the injections were tested on more than 1,600 people, with 90 per cent reporting it reduced the fat under their chin after two years, Kythera said。
不過臨床試驗中已有超過1600人接受了注射治療，兩年后有90%的患者表示他們下巴上的贅肉已經(jīng)得到消除。
As part of the trial, ATX-101 was injected up to four or six times, based on the amount and volume of the fat under the chin。
依據(jù)下巴中的脂肪含量，試驗過程中注射4到6次ATX-101。
However, common side effects included pain in the chin, numbness, bruising, swelling, redness, firmness, itching, a burning or prickling sensation and nodules。
然而也會產(chǎn)生一些常見的副作用，包括下巴疼痛、肌肉麻痹、瘀傷、腫脹，發(fā)紅、硬化、發(fā)癢、產(chǎn)生灼燒和刺痛感以及長出結(jié)節(jié)。
